Search | Clinical Trials Finder

Conditions: Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions: Standard number of injection sites, Reduced number of injection sites; Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions: Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more

Conditions: Overactive Bladder
Interventions: Active TENS, Sham TENS; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neurogenic Detrusor Overactivity
Interventions: Trospium-Releasing Intravesical System (TAR-302-5018); Drug
Lead sponsor: Taris Biomedical LLC; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Troy, Michigan • Charlotte, North Carolina • Virginia Beach, Virginia + 1 more

Conditions: Neurogenic Detrusor Overactivity
Interventions: Darifenacin; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
Interventions: OnabotulinumtoxinA, Placebo (Normal Saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Mountlake Terrace, Washington

Conditions: Neurogenic Detrusor Overactivity
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Tarrytown, New York • Cincinnati, Ohio

Conditions: Neurogenic Detrusor Overactivity, Pediatric
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Urinary Incontinence
Interventions: OnabotulinumtoxinA; Biological
Lead sponsor: Allergan; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Overactive Bladder Syndrome
Interventions: Device Morpheus8V; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Corona del Mar, California • Knoxville, Tennessee

Conditions: Overactive Detrusor, Neurogenic Bladder
Interventions: Oxybutynin, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 16 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 10
States / cities: Loma Linda, California • Orange, California • Aurora, Colorado + 7 more

Conditions: Detrusor Overactivity
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
Interventions: Patient-directed follow up; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions: Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more

Conditions: Prostate Adenocarcinoma
Interventions: Fesoterodine, Placebo oral tablet; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 30 Years to 90 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Dysfunction, Overactive Bladder, BPH With Urinary Obstruction
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bladder Function
Interventions: cystometry (CMG), polysomnography (PSG); Procedure
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Urinary Bladder, Overactive
Interventions: MagPro R30; Device
Lead sponsor: EMKinetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions: Extended Urine Culture; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Overactive Bladder
Interventions: hMaxi-K, Placebo; Drug · Other
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Branford, Connecticut

Conditions: Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions: Botox Instillation, DMSO Instillation; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Detrusor Hyperreflexia
Interventions: Oxybutynin transdermal system; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 6
States / cities: Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Search by objective public record fields.

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

Migraine Medication Effects on Urinary Symptoms

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

TENS Used for Pain Management During Office Cystoscopy Botox Injections

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

Optimal Injection Interval for Intra-Detrusor Botulinum Toxin

Refractory Urge Incontinence and Botox Injections

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

Over Active Bladder Instillation Study - Botox

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition